Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-IgE therapy

P Jardieu1

  • 1Department of Immunology, Genentech Inc, San Francisco, CA 94080, USA.

Current Opinion in Immunology
|December 1, 1995
PubMed
Summary
This summary is machine-generated.

Researchers are developing anti-IgE antibodies to control the allergic cascade by blocking immunoglobulin E (IgE) binding. These novel therapies show promise for treating allergic diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization.

The Journal of allergy and clinical immunology·2001
Same author

Effects of humanized monoclonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients.

Transplantation·2000
Same author

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis.

Journal of the American Academy of Dermatology·2000
Same author

Treatment of allergic airways disease with anti-IgE.

Allergy·1998
Same author

Therapeutic potential of anti-IgE antibodies.

Current opinion in immunology·1998
Same author

Expression of the high-affinity immunoglobulin E receptor alpha-subunit in human blood eosinophils.

International archives of allergy and immunology·1997

Area of Science:

  • Immunology
  • Allergy Research
  • Therapeutic Development

Background:

  • The immunoglobulin E (IgE) response is central to allergic reactions.
  • Current research aims to control IgE at synthesis or effector phases.
  • Interfering with IgE's high-affinity receptor and cytokine signaling are key strategies.

Purpose of the Study:

  • To explore novel therapeutic strategies for allergic diseases.
  • To investigate the potential of anti-IgE antibodies as IgE antagonists.

Main Methods:

  • Focus on interfering with IgE binding to its high-affinity receptor.
  • Antagonizing cytokine and cell-associated molecule interactions (CD40, CD23) involved in IgE synthesis.
  • Development and investigation of anti-IgE antibodies.

Related Experiment Videos

Main Results:

  • Anti-IgE antibodies have been developed as potent IgE antagonists.
  • These antibodies are currently undergoing clinical investigation.

Conclusions:

  • Controlling the IgE response offers a significant therapeutic avenue for allergic diseases.
  • Anti-IgE antibodies represent a promising new class of therapeutics for managing allergic conditions.